drugset / Trial / NCT00046787
Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether OSI-211 (Liposomal Lurtotecan) is an effective and safe treatment for patients with recurrent small cell lung cancer.
Timeline
- Start
- 2002-09
- Primary completion
- —
- Completion
- 2003-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OSI-211 | Unknown | — | — |